Apyx Medical (APYX) Cost of Revenue (2011 - 2026)

Apyx Medical has reported Cost of Revenue for 16 years, with the latest figure at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 21.25% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $20.6 million (up 13.11% YoY), and the FY2025 full-year result was $19.8 million, up 5.65% from the prior year.
• Cost of Revenue for Q1 2026 stood at $4.6 million, down from $7.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $7.2 million in Q4 2025, with the low at $3.4 million in Q3 2022.
• Historically, Cost of Revenue has averaged $4.5 million across 5 years, with a median of $4.4 million in 2022.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 53.85% — and 2025, when it retreated 12.34%.
• Apyx Medical's Cost of Revenue stood at $4.4 million in 2022, then surged by 31.19% to $5.7 million in 2023, then retreated by 8.29% to $5.3 million in 2024, then jumped by 36.27% to $7.2 million in 2025, then slumped by 36.29% to $4.6 million in 2026.
• The last three Cost of Revenue figures came in at $4.6 million (Q1 2026), $7.2 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.